Replimune is developing a novel class of oncolytic immunotherapies aimed at treating difficult-to-treat cancers by igniting a patient-specific immune response. These therapies are designed to be tolerable and effective in the local killing of tumors.

Replimune

Domain Not Resolving

HSTS

DNSSEC

COVID-19

Mobile Optimized

Akamai Hosted

Comcast

Drupal

Adobe Dynamic Tag Management

Drupal 10

Chief Medical Officer

Andrea Pirzkall

Chief Operating Officer

Colin Love

Chief Financial Officer, Treasurer, Secretary, and Compliance Officer

Jean Franchi

Chief Business Officer

Pamela Esposito

Chief Development Operations Officer

Tanya Lewis

Vice President Finance

Andrew Schwendenman

Vice President, Head of Medical Safety and Pharmacovigilance

Anton Trochanov

VP, Global Development Operations

April Dovholuk

Vice President Financial Planning & Analysis

Craig Corsetti

Vice President, Medical Writing

Debra Stamper

Otello Stampacchia

Brett Zbar

Robert Coffin

Paolo Pucci

Dieter Weinand

Sander Slootweg

Kapil Dhingra

Hyam Levitsky

Founder

Joseph Slattery

Lead Independent Director (Past), Chairman of Audit Committee, Member of Compensation Committee

Junhong Zhu

Head of Biometrics

Sushil Patel

Chief Executive Officer and Executive Chairman

Philip Sparke

Chris Sarchi

Chief Commercial Officer

Emily Hill

Chief Strategy Officer

East Coast Biotechnology Companies

Greater Boston Area Companies With More Than 100 Employees

United States Public Companies With More Than 10 Employees

Therapeutics Companies With More Than $1M in Revenue (Top 10K)

Replimune Group develop the next generation of ‘oncolytic immunotherapies’ for the treatment of cancer. Replimune is developing novel, proprietary products intended to improve both the direct anti-tumor effects of selective virus replication and the potency of the immune response to the tumor antigens released. The Company’s Immulytic™ platform is designed to maximize systemic immune activation, in particular to tumor neoantigens, through robust viral mediated immunogenic tumor cell killing and the delivery of optimal combinations of immune activating proteins to the tumor and draining lymph nodes. The approach is expected to be highly synergistic with immune checkpoint blockade and other approaches to cancer treatment. Replimune intends to progress these therapies rapidly through clinical trials and to combine with other immuno-oncology products with complementary mechanisms of action at an early stage. 

Post-IPO Equity - Replimune Group

Hercules Capital

Post-IPO Debt - Replimune Group

Bain Capital Life Sciences

Foresite Capital

Series B - Replimune Group

Atlas Venture

Omega Funds

Series A - Replimune Group

Seed Round - Replimune Group

Woburn

Massachusetts

United States

North America

Replimune Group

Replimune ignites its stock with phase I/II data in melanoma

Replimune Group Shares Rally on Skin Cancer Study Data

Replimune Group Shares Rise 8% After $100M Private Placement Financing

Replimune secures $100 million for cancer therapy scale-u

Replimune group's chief medical officer sells shares worth over $119k By Investing.com

Replimune Group presents positive data from RP1 and RP2 programs at ASCO

Replimune group executive sells $14,868 in stock By Investing.com

Philippines

Asia

United Kingdom

Europe

Czech Republic

India

HTML5

Google Analytics

Office 365

Apache Server

Wordpress

Gravity Forms

Google Fonts

Cloudflare CDN

Microsoft Outlook

jQuery

Replimune Group Inc is a clinical-stage biotechnology company. It uses a proprietary RPx platform to design and develop product candidates that are intended to maximally activate the immune system against solid tumors. The RPx platform is based on a proprietary, engineered strain of herpes simplex virus 1, or HSV-1, backbone with payloads added to maximize immunogenic cell death and the induction of a systemic anti-tumor immune response. The company focuses on developing oncolytic immunotherapies for the treatment of cancer. Its pipeline products include RP1, RP2, and RP3.

Replimune Group, Inc.

news_impact_assignment_basic

key_people

merger_acquisitions

network_dossier

public_peers

news_daily_refresh

news_processing_daily_refresh

news_impact_assignment_daily

news_processing_basic

legal

legal_dossier

bundesanzeiger

events_dossier

partnerships_market_presence_dossier

partnerships_market_presence

company_dossier

network

strategic_challenges

industry_trends

strategic_challenges_dossier

industry_trends_dossier

company_summary

events

network_mapping

transactions_dossier

swot_dossier

signals

financial_statements

crunchbase_trigger

crunchbase_profile

li_profile

financials_download_nd

private_financials

swot_analysis

financial_legal_advisories

company_structure

industry_analysis

financial_analysis

funding_rounds_analysis

regulatory_analysis

competition_analysis

news_impact_assignment_advanced

news_processing_advanced

news_advanced

purchaser_profile

network_onboarding

translate_crunchbase_fundingrounds

peers

customer_profile

news_basic

valuation

news impact assignment basic	general
public peers	general	Sep 5, 2024 4:51 PM	2e8ab105
news daily refresh	general
news processing daily refresh	general
news impact assignment daily	general
news processing basic	general	Sep 5, 2024 5:03 PM	17986e98
company summary	general
signals	general
crunchbase trigger	general	Oct 29, 2024 5:10 PM	609894ba
crunchbase profile	general	Oct 30, 2024 9:13 AM	1c183b02
li profile	general
translate crunchbase fundingrounds	general	Nov 6, 2024 3:12 PM	fba573ef
peers	general	Sep 5, 2024 4:51 PM	c3698332
news basic	general	Sep 5, 2024 4:51 PM	94baeca7
bundesanzeiger	filings
financials download nd	financials
private financials	financials

COM:REPLIMUNE

Replimune

Last Close

11.05

22/11 21:00

Market Cap

961.18M

Beta: -

Volume Today

6.07M

Avg: -